|

Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers

RECRUITINGSponsored by Assistance Publique - Hôpitaux de Paris
Actively Recruiting
SponsorAssistance Publique - Hôpitaux de Paris
Started2024-05-22
Est. completion2028-05-22
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06408402

Summary

The primary objective of the PGL.EXPO-2 study is to test the hypothesis that exposure (occupational, environmental and/or domestic) to succinate dehydrogenase inhibitors (SDHi) could contribute to tumor emergence in subjects carrying a germline mutation in one of the SDHx genes.The primary endpoint will be the proportion of subjects (cases or controls) exposed to SDHi and the association with paraganglioma risk. In addition, a blood sample (10 ml on EDTA) will be proposed to the participants to the study

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Cases: SDHx mutation carriers diagnosed for a SDHx-related tumor
* Controls: SDHx mutation carriers with no SDHx-related tumor

Exclusion Criteria:

* Incapacity to exercise free and informed consent for the study
* Patient under tutorship or guardianship or legal safeguard

Conditions5

CancerEnvironmental ExposureSDH Gene MutationSDH-Related Familial ParagangliomaSDHx-Related Syndromes

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.